Source: Fierce Healthcare — 2026-08-04
Summary
QuantHealth, a Tel Aviv/New York AI company, closed a $45M Series B led by Qumra Capital with Sanofi Ventures participating, bringing total funding to roughly $70M. The company's platform simulates patient-level biology to predict clinical trial outcomes before a single patient is enrolled, and per CEO Orr Inbar has already simulated over 600 trials across 30 disease indications at up to 90% predictive accuracy, working with 12 of the top 20 global pharmaceutical companies.
Key Takeaways
- The platform simulates patient-level biological responses to predict how a clinical trial will play out before real patients are recruited — aimed at the design stage, not analysis after the fact.
- Reported track record: 600+ trials simulated across 30 disease indications, with predictive accuracy reaching up to 90% — concrete, testable figures rather than a vague accuracy claim.
- The company is actively expanding indication coverage toward 40+, with a stated focus on oncology, cardiometabolic disease, and inflammation.
- 12 of the top 20 global pharmaceutical companies are already customers, which is a meaningful commercial validation signal for a Series B-stage company.
- Sanofi Ventures' participation as a strategic pharma investor, alongside financial lead Qumra Capital, suggests real interest from a trial sponsor rather than purely financial backing.
Reel Script
Hook: A failed clinical trial can burn hundreds of millions of dollars and years of work before anyone learns the drug simply wasn't going to work. A startup just raised $45 million on the claim that it can predict that outcome before a single patient is ever enrolled.
Core Concept: Clinical trials are extraordinarily expensive to run and even more expensive to get wrong — recruiting patients, running the trial for years, and only then discovering the drug didn't hit its endpoints. QuantHealth's pitch is to move that discovery earlier by simulating the biology first: instead of waiting for real patients to reveal how a drug performs, the platform models patient-level biological responses computationally, essentially running a virtual version of the trial before committing the time and capital to run the real one. The goal isn't to replace clinical trials — regulators still require real trial data — but to catch a trial that's unlikely to succeed, or to refine its design, before that capital gets spent.
Hands-On: The number worth putting on screen is the track record so far: over 600 trials simulated across 30 disease indications, with predictive accuracy reaching up to 90% in the company's reported results — and they're now pushing indication coverage past 40, with oncology, cardiometabolic disease, and inflammation as the near-term focus areas. The customer list is the other concrete signal here: 12 of the top 20 global pharmaceutical companies are already using this, which is a meaningfully higher bar than a typical early-stage healthtech pilot. And the $45 million round wasn't purely financial — Sanofi Ventures, the strategic arm of an actual trial sponsor, participated alongside lead investor Qumra Capital, which reads as a pharma company betting on this prediction capability with its own money, not just a VC's.
Takeaway: If accurate, before-enrollment trial simulation is one of the more consequential applications of AI in medicine right now, because the cost of a failed trial is measured in years and hundreds of millions, not just dollars per query. Watch whether QuantHealth's 90% accuracy claim holds up against real trial outcomes at scale before treating this as proven — but the pharma customer list already suggests the industry isn't waiting to find out.